Ana Hickey

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Body Mass Index

Top Venues

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Arihiro Kiyosue, Julia P Dunn, Xuewei Cui, Ana Hickey, Tetsuaki Hirase, Takeshi Imaoka, Robert J Heine
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme). Diabetes, obesity & metabolism 25 (4) (2023)
Arihiro Kiyosue, Julia P Dunn, Xuewei Cui, Ana Hickey, Tetsuaki Hirase, Takeshi Imaoka, Robert J Heine
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme). Diabetes, obesity & metabolism 25 (4) (2023)
Arihiro Kiyosue, Julia P Dunn, Xuewei Cui, Ana Hickey, Tetsuaki Hirase, Takeshi Imaoka, Robert J Heine
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme). Diabetes, obesity & metabolism 25 (4) (2023)
Carel W le Roux, Emily R Hankosky, Duzhe Wang, Raleigh E Malik, Maria Yu, Ana Hickey, Hong Kan, Mathijs C Bunck, Adam Stefanski, Luis-Emilio Garcia-Perez, Sean Wharton
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison. Diabetes, obesity & metabolism (2023)
Arihiro Kiyosue, Julia P Dunn, Xuewei Cui, Ana Hickey, Tetsuaki Hirase, Takeshi Imaoka, Robert J Heine
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme). Diabetes, obesity & metabolism (2022)
Arihiro Kiyosue, Julia P Dunn, Xuewei Cui, Ana Hickey, Tetsuaki Hirase, Takeshi Imaoka, Robert J Heine
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS program). Diabetes, obesity & metabolism (2022)